Alphamab Oncology, a Chinese biopharma company that specializes in the development of innovative biologics for cancer therapy, announced on Tuesday that it has secured US$60 million in a series B round of financing led by New York-based asset management firm Hudson Bay Capital Management. Existing investors including Chinese biotech and healthcare-focused venture capital fund China […]

Chinese Biopharma Firm Alphamab Oncology Gets $60M In Series B Round comes originally from China Money Network. All Rights Reserved.